ArticleCureus2026
Efficacy of Sublingual Misoprostol Versus Intravenous Tranexamic Acid in Reducing Blood Loss Among Full-Term Pregnant Women Undergoing Primary Lower Segment Caesarean Section: A Randomized Controlled Trial.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPostpartum hemorrhage remains a major cause of maternal morbidity and mortality, with caesarean section being associated with increased intraoperative blood loss. Pharmacological agents such as misoprostol and tranexamic acid have been used prophylactically to reduce blood loss during lower segment caesarean section (LSCS); however, evidence directly comparing their efficacy is limited. This study aimed to compare the efficacy and safety of sublingual misoprostol and intravenous tranexamic acid in reducing intraoperative blood loss during primary LSCS. MATERIALS AND
methodsThis hospital-based, open-label, randomized controlled trial included 140 women with singleton term pregnancies undergoing primary LSCS. Participants were randomized equally to receive either 600 µg sublingual misoprostol or 1 g intravenous tranexamic acid immediately before skin incision. The primary outcome was intraoperative blood loss measured using a standardized gravimetric method. Secondary outcomes included postoperative fall in haemoglobin, requirement for additional uterotonic agents or blood transfusion, and adverse drug effects.
resultsBaseline demographic and obstetric characteristics were comparable between the two groups. Mean intraoperative blood loss was significantly lower in the misoprostol group than in the tranexamic acid group (316.0 ± 158.0 mL vs. 518.5 ± 233.1 mL; p < 0.001). Women receiving misoprostol also had a significantly smaller postoperative fall in haemoglobin and required fewer additional uterotonic agents (2 (2.9%) vs. 11 (15.7%); p = 0.009) and blood transfusions (1 (1.4%) vs. 9 (12.9%); p = 0.016). Fever and shivering were more common with misoprostol, whereas hypotension occurred more frequently in the tranexamic acid group (all p < 0.05).
conclusionSublingual 600 µg misoprostol was more effective than 1 g intravenous tranexamic acid in reducing intraoperative blood loss during primary LSCS. It was associated with a smaller postoperative decline in haemoglobin and a reduced need for additional uterotonic agents and blood transfusion, while maintaining an acceptable safety profile. These findings support the use of sublingual misoprostol as an effective and economical option for preventing excessive blood loss during primary LSCS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.